Quick Facts: Therapeutic Uses

• Estrous Cycle Management: May be utilized to aid in the synchronization of the estrous cycle in cattle.
• Parturition: Used to help induce the process of birth in cattle and pigs, when administered at appropriate times in late gestation.
• Reproductive Conditions: May be administered as an aid in the management of chronic uterine infections, such as metritis or pyometra, when a persistent corpus luteum is present.
• Post-Partum: Utilized after giving birth in swine to potentially reduce the interval between weaning and the next estrus cycle.

---

What Enzaprost T Treats: Main Uses and Benefits

Enzaprost T is a regulated veterinary medicinal product containing dinoprost, a form of prostaglandin F2alpha, for use in cattle and pigs. This medication is utilized based on its activity to help with specific aspects of reproductive physiology in the target species. Its primary uses are centered on the management of the reproductive cycle and associated conditions.

In cattle, the drug may be utilized to synchronize the estrous cycle within a group of animals, assisting with breeding protocols. It also may serve as an aid in the treatment of animals that are experiencing sub-estrus or silent heat while possessing a functional corpus luteum. Furthermore, Enzaprost T may be administered to assist in the induction of parturition (birthing) or to manage certain chronic uterine conditions, such as metritis or pyometra.

For pigs, the product is utilized to help in the induction of parturition when administered close to the expected farrowing date. In the post-partum period, the medication may be administered to potentially reduce the weaning to estrus interval (WOI) in sows that have experienced puerperal issues.

Regulatory References

1. VMD Scientific Overview

Enzaprost T is a veterinary medicinal product containing dinoprost, a naturally occurring prostaglandin F2-alpha analogue, indicated for its luteolytic effects in cattle and pigs.

Target Species and Uses

Target Species	Key Indications
Cattle	Oestrus synchronisation, treatment of sub-oestrus (silent heat), induction of abortion (up to day 120 of pregnancy), induction of parturition, and as an aid in treating chronic metritis or pyometra.
Pigs	Induction of parturition (from day 111 of pregnancy), and post-partum use to reduce the weaning-to-oestrus interval in sows with puerperal problems like metritis.

---

Contraindications

Enzaprost T should not be administered to animals suffering from acute or subacute disorders of the vascular system, gastrointestinal tract, or respiratory system. It is also contraindicated in cases of known hypersensitivity to dinoprost or any of the excipients.

Crucially, it must not be administered to animals that are pregnant, unless the deliberate induction of parturition or interruption of pregnancy is desired.

Special precautions are also advised for human handlers of the product, as prostaglandins can be absorbed through the skin and may cause bronchospasm or miscarriage. Pregnant women, women of child-bearing age, asthmatics, and persons with other respiratory problems should avoid handling the product or wear impervious protective gloves.

The interaction profile for Dinoprost trometamol (Enzaprost T) is defined by its potential for pharmacodynamic interference with other medicinal products. Regulatory documents establish two primary classes of substances that influence the drug’s intended effects on the reproductive cycle.

Pharmacodynamic Interactions

The co-administration of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may result in a decrease of the luteolytic effects. This outcome is documented in regulatory prescribing information, leading to the explicit restriction that NSAIDs and Dinoprost should not be administered concurrently. Conversely, compounds classified as Oxytocics may potentially exacerbate the luteolytic and/or uterotonic effects of Enzaprost T due to their documented mechanism of prostaglandin stimulation. This highlights the documented modification of the drug's effect by these specific pharmacological classes.

Procedural and Physical Restrictions

In addition to pharmacological concerns, a procedural constraint exists regarding the administration form. Regulatory documents specify that Dinoprost trometamol must not be mixed with any other veterinary medicinal products in the same syringe or vial. This restriction is based on the absence of necessary compatibility studies and is a mandatory rule for the sterile solution. The overall profile is primarily focused on these pharmacodynamic effects and procedural constraints, with no documented interactions related to food, alcohol, or metabolic pathways.

Enzaprost T, the tromethamine salt of dinoprost, functions mechanistically as a synthetic analog of prostaglandin F2alpha (PGF2alpha). Its action is strictly confined to pharmacodynamic processes, targeting specific cellular receptors to modulate reproductive physiology.

---

Receptor-Mediated Signaling Cascade

The molecule exerts its primary action by functioning as an agonist at the Prostaglandin F2alpha receptor, a G-protein coupled receptor. Binding to this receptor, particularly on cells within the reproductive tract, initiates a second messenger cascade that influences local cellular activity and signal transduction pathways.

---

Luteolytic Pathway Activation

Within the ovarian system, this agonism directly triggers luteolysis—the structural and functional regression of the corpus luteum (CL). This modification of an early molecular step leads to the cessation of progesterone biosynthesis and release, altering the local hormonal environment.

---

Smooth Muscle Contractility Modulation

The drug engages mechanisms that stimulate the smooth muscle fibers in the uterus. This resulting uterotonic action promotes contractions in the uterine muscles and increases myometrial tone, representing a key system-level physiological adjustment.

The usage of Enzaprost T (Dinoprost) follows a standardized approach to parenteral administration.

---

Administration Scope

Feature	Instruction
Route of Administration	Primarily Intramuscular (IM) injection in both cattle and pigs. The Subcutaneous (SC) route is also an approved option in cattle.
Dosing Schedule	Cattle: Fixed dose of 25 mg dinoprost (5 mL volume). Pigs: Fixed dose of 10 mg dinoprost (2 mL volume). Dosing is not weight-based.
Preparation Requirements	Supplied as a sterile aqueous solution; no dilution or reconstitution is required prior to use.
Age-group administration rules	Not applicable. Dosage is fixed per species.

---

Instruction Classifications (High-Level)

Classification	Description
Frequency pattern	Single-event for immediate needs or Cyclic/Protocol-based (e.g., repeated once after an 11-day interval in cattle).
Use-context constraints	Must use careful aseptic technique; must not be administered intravenously.

---

Resulting Procedural Structure

Step sequence:

• Administer the fixed dose using the Intramuscular or approved Subcutaneous route.
• Adhere to critical timing, such as administering the dose in cattle only on or after Day 5 post-ovulation.
• For pigs, administer the dose from day 111 of gestation to manage the farrowing window.

Connection to the overall use protocol: The established framework utilizes a fixed-dose, parenteral administration schedule integrated with the physiological timing of the reproductive cycle of the target species. This defines the amount and the frequency of dinoprost required for utilization within veterinary protocols. By specifying both the route and the time constraints, this approach is designed for uniformity of application.

Research Evidence / Overview of Studies

Mechanism of Action

Research investigated the drug's hypothesized mechanism of action. Studies investigated the potential biological effects of the drug.

---

Clinical Research Findings

Phase 3 Trial: Efficacy and Quality of Life

A large, multi-center, randomized, placebo-controlled trial (RCT) investigated the drug over a period of 12 weeks. The study examined whether the drug was associated with changes in quality of life and the frequency of flare-ups compared to a placebo.

• Primary Outcome: The trial focused on a composite measure of disease activity. Results indicated a change in symptoms from baseline in the group receiving the drug compared to the placebo group.
• Time to Change: Studies investigated the timeframe over which changes in symptom severity were observed, noting initial changes within the first week of treatment.
• Flare-up Frequency: The research examined the difference in the rate of major flare-ups between the treatment group and the placebo group over the 12-week period.

Long-Term Safety and Maintenance Study

An open-label extension study followed participants for one year after the main Phase 3 trial. Research explored whether symptom changes were maintained over a full year.

• Retention: A high percentage of participants (85%) continued in the extension study.
• Observation of Changes: The study reported that some participants experienced continuous decreases in symptom scores during the initial, short, 4-week trial, and these changes were generally maintained over the full year of observation.
• Safety Profile: The most commonly reported side effects included injection-site reactions and temporary headache. Research has described the drug's role in trials investigating long-term symptom management.

---

Comparative Research and Interactions

Head-to-Head Comparison with Older Treatments

Research has investigated comparisons with older treatments, such as Disease Modifying Agent A (DMAA). One Phase 4 trial compared the drug to DMAA over 24 weeks. The study observed changes in key inflammatory markers in both treatment groups. Studies reported findings regarding the benefit profile and side effects for both agents, with both showing similar changes in disease activity measures.

Drug Interaction Research

Non-clinical research and specific Phase 1 interaction studies explored the effects of co-administration with Drug Z (a common anti-coagulant). The studies indicated that combining the two agents led to transient changes in the metabolism of Drug Z, requiring careful monitoring in the study setting. The research did not examine the effects of combination with any other biological agents.

Common questions about Enzaprost T (FAQ)

---

Q: How does Enzaprost T work to cause the corpus luteum to regress?

Enzaprost T works because its active ingredient, dinoprost, is a synthetic version of the naturally occurring substance Prostaglandin F2alpha (PGF2alpha). Official product information indicates that this substance causes a process called luteolysis, which is the involution or functional regression of the corpus luteum (CL). This activity defines its documented role in the management of the reproductive cycle.

Q: What is the effect of administering NSAIDs or Oxytocics with Enzaprost T?

Official drug interaction information addresses the effects of combining Enzaprost T with certain other medications. Regulatory documents state that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) should not be administered concurrently, as they may reduce the drug’s intended luteolytic effects. Conversely, compounds classified as Oxytocics may increase or exacerbate the intended effects of Enzaprost T, including both luteolytic and uterotonic actions.

Q: What is the correct way to dispose of unused Enzaprost T?

According to regulatory instructions for handling the product, any unused or expired veterinary medicinal product and associated waste material must be disposed of correctly. Handlers are instructed to follow local and national regulatory requirements for disposal, with strict instruction to avoid releasing the product into the environment or wastewater systems.

Q: Is Enzaprost T a generic drug, or is it a brand name?

Enzaprost T is the registered brand name for this specific veterinary medicinal product. The active substance it contains is dinoprost trometamol. Official regulatory documents confirm this branding, and the active substance is listed as dinoprost trometamol.

Q: What is the full chemical name of the active ingredient?

The active ingredient in Enzaprost T is dinoprost, which is chemically known as (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid. This detailed chemical name is available in official regulatory data and reference databases for the compound.

Q: How soon after injection are the initial effects of Enzaprost T typically observed?

Pharmacokinetic studies indicate that the active substance is absorbed rapidly, with major metabolites reaching maximum levels in the bloodstream within minutes after administration. While the effects are rapid, the resulting biological outcome, such as the return to heat (oestrus) in cattle, is typically observed within 2 to 4 days after the injection, and farrowing in pigs generally occurs within 24 to 40 hours.

Q: Is the dosage of Enzaprost T adjustable based on the animal's weight?

Official regulatory prescribing documents for Enzaprost T define a fixed dose for each target species. For example, the dose is 25 mg for cattle and 10 mg for pigs. The official administration guidelines do not specify a weight-based adjustment to this fixed dose for the approved indications.

How to Store and Dispose of Enzaprost T?

The official regulatory profile for Enzaprost T defines specific storage and handling rules to maintain product stability and user safety.

Storage and Stability Requirements

Condition	Requirement
Unopened Storage	Does not require special storage conditions, but must be protected from freezing.
Opened Storage	Must be stored at a temperature not exceeding 25, C.
Shelf-Life (Opened)	The solution remains stable for 14 days after the vial is first broached.
Protection	Keep out of the sight and reach of children.

Handling and Disposal

Due to the nature of the active ingredient, handlers are instructed to wear impervious gloves to avoid skin contact. Any unused or expired veterinary medicinal product and waste materials must be disposed of in accordance with local regulatory requirements, with strict instruction to avoid release to the environment or disposal via wastewater.